call Toll Free (US/Canada) : +1 866 658 6826 | call +1 425 320 4776 | call (UK) : +44 1865 60 0662 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Blueweave
Patient Derived Xenograft Model Market
Inquire Before Buying Request for Sample

Patient Derived Xenograft Model Market

Home Healthcare And Pharmaceutical Patient Derived Xenograft Model Market

Patient-Derived Xenograft (PDX) Model Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Type (Mice Model, Rats Model); By Tumor Type (Gastrointestinal Tumor Model, Gynecological Tumor Model, Respiratory Tumor Model, Urological Tumor Models, Hematological Tumor Models); By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions); By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

  • Published Date: November 2023
  • Report ID: BWC23932
  • Available Format: PDF
  • Page: 400

Report Overview

The rising demand for personalized medicine and growing cancer incidence are projected to propel the expansion of the global patient-derived xenograft (PDX) model market during the forecast period between 2023 and 2029.

Global Patient-Derived Xenograft (PDX) Model Market - Industry Trends & Forecast Report, 2029

Global patient-derived xenograft (PDX) model market size was estimated at USD 312.56 million in 2022. During the forecast period between 2023 and 2029, the size of global patient-derived xenograft model market is projected to grow at a CAGR of 13.1% reaching a value of USD 654.91 million by 2029. Major growth drivers for the global patient-derived xenograft (PDX) model market include an increasing in cancer incidence, the growing research and development efforts in the pharmaceutical sector, rising consumer demand for personalized medications, and continued backing for cancer research from both public and private sectors. Crucial preclinical development procedures, involving strict adherence to the FDA Good Manufacturing Practices (GMPs), such as drafting clinical plans and preparing drug products, are of paramount importance. Governments’ initiatives like Small Business Innovative Research and Small Business Technology Transfer Grants provide crucial financial backing and guidance for preclinical programs and their related components. Anticipated global demand for patient-derived xenograft (PDX) models is on the upswing. PDX data serves to streamline the selection of suitable PDX models and in vivo efficacy trials, leading to significant time and cost savings. The PDX model entails the direct implantation of patient tumor tissue into an immune-compromised animal, preserving vital cell-tumor microenvironment interactions. This model has demonstrated its value in preclinical drug testing, biomarker discovery, and co-clinical investigations. The introduction of immunodeficient rats will facilitate the development of PDX models using rat species. Also, the growth of research and development activities, coupled with the sustained support from government and private sectors for cancer research, further propels market expansion.

Patient-Derived Xenograft Model Market

Global Patient-Derived Xenograft (PDX) Model Market – Overview

The global patient-derived xenograft (PDX) model market refers to the market encompassing the use of specialized laboratory mice or other animals to implant human tumor tissues. These PDX models are created by directly transplanting cancerous tissue from a patient into an immune-deficient animal, preserving the essential interactions between human cancer cells and the surrounding microenvironment. They serve as vital tools for preclinical research in oncology, allowing scientists and researchers to study the behavior of human tumors in a more clinically relevant setting. The market includes the development, utilization, and supply of PDX models to facilitate drug testing, biomarker discovery, and co-clinical investigations in the quest for more effective cancer treatments and personalized medicine.

Global Patient-Derived Xenograft (PDX) Model Market

Growth Drivers

Growing Prevalence of Cancer Incidence

The growing incidence of cancer has led to an increased interest in the utilization of PDX models as a valuable tool for understanding cancer characteristics, developing innovative treatments, and predicting treatment outcomes. Recent efforts have focused on creating PDX models for ovarian tumors to gain insights into their development. The success of engraftment varies across different malignancies and tumor types. For cervical cancer, the engraftment success rate ranged from 66.7% to 71.4%, while endometrial cancer PDX models achieved rates from 60% to 86%. Ovarian cancer PDX models demonstrated engraftment rates between 45.5% and 100%. This rising trend in cervical and ovarian cancer cases is a driving force behind the industry's growth.

Restraints

High Initial Investment Costs

The global patient-derived xenograft (PDX) model market faces constraints due to the high costs associated with creating and maintaining PDX models. Notably, the technical expertise required for successfully establishing and managing these models presents a significant barrier. The intricate process demands specialized knowledge and skills, limiting accessibility for many researchers. These financial and technical challenges can hinder the widespread adoption of PDX models in cancer research and drug development, potentially slowing down advancements in personalized medicine and treatment strategies.

Impact of COVID-19 on Global Patient-Derived Xenograft (PDX) Model Market

COVID-19 pandemic adversely affected the global patient-derived xenograft (PDX) model market. With lockdowns, restrictions on laboratory operations, and supply chain interruptions, research activities were temporarily halted or delayed. Access to resources and animal models required for PDX model development became constrained. Furthermore, prioritization of COVID-19 research led to a diversion of resources and funding. However, as the pandemic highlighted the importance of personalized medicine, it also emphasized the significance of PDX models in cancer research. As restrictions eased, the market rebounded, driven by the growing need for innovative cancer treatments and therapies.

Global Patient-Derived Xenograft (PDX) Model Market

Segmental Coverage

Global Patient-Derived Xenograft (PDX) Model Market – By Type

Based on type, the global patient-derived xenograft (PDX) model market is bifurcated into Mice Model and Rats Model segments. The mice model segment holds a higher share in the global patient-derived xenograft model market by type. The mouse is the primary mammalian model for studying human health and disease due to its economic size, prolific breeding, and extensive knowledge of mouse physiology, anatomy, and genes. Researchers can manipulate mouse genes, making it valuable in cancer research, from identifying potential treatments to understanding cancer biology. The growing use of mouse models in cancer research and increased investments from public and private sectors drive segment growth. Genetically engineered mouse models are designed to induce tumorigenesis, while various regions, including the European Union, the United States, and China, have increased research and development investments in the healthcare sector, promoting disease research and innovative treatments. Consequently, significant segment growth is expected during the forecast period.

Patient-Derived Xenograft Model Market Size

Global Patient-Derived Xenograft (PDX) Model Market – By Tumor Type

Based on tumor type, the global patient-derived xenograft (PDX) model market is divided into Gastrointestinal Tumor Model, Gynecological Tumor Model, Respiratory Tumor Model, Urological Tumor Models, and Hematological Tumor Models segments. The respiratory tumor model segment holds the highest share in the global patient-derived xenograft model market by tumor type. This is primarily due to the increased prevalence of respiratory cancers worldwide, leading to a heightened focus on developing models to study these tumors. Lung cancer, for instance, remains a leading cause of cancer-related deaths globally, necessitating a robust platform for research. PDX models for respiratory tumors enable researchers to closely mimic and study these cancers in vivo, facilitating the development of innovative therapies and treatment strategies. This growing demand for effective respiratory tumor models propels the segment's dominance in the global PDX model market.

Global Patient-Derived Xenograft (PDX) Model Market – By End User

On the basis of end user, the global patient-derived xenograft (PDX) model market is split into Pharmaceutical & Biotechnology Companies and Academic & Research Institutions segments. The pharmaceutical & biotechnology companies segment holds a higher share in the global patient-derived xenograft model market by end user. This is primarily because pharmaceutical and biotech companies are at the forefront of cancer research and drug development. They heavily rely on PDX models to test potential drug candidates, assess their efficacy, and better understand tumor biology. These models offer a crucial bridge between preclinical research and clinical trials, allowing these companies to make informed decisions about drug development. As a result, their substantial involvement in cancer research and therapeutics drives their prominent share in the PDX model market.

Patient-Derived Xenograft Model Market Share

Global Patient-Derived Xenograft (PDX) Model Market – By Region

The in-depth research report on the global patient-derived xenograft (PDX) model market covers various country-specific markets across five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America is expected to lead the global patient-derived xenograft (PDX) models market. This dominance can be attributed to various factors, including the increasing cancer cases, substantial investments from both public and private sectors, and the presence of key industry players in the region. Notably, key developments like the Breast Cancer Society of Canada granting USD 350,000 for breast cancer research projects demonstrate the commitment to advancing cancer care. According to the WHO, an estimated 28,000 Canadians were expected to be diagnosed with breast cancer in 2022, underlining the growing significance of cancer research in North America.

Competitive Landscape

Major players operating in the global patient-derived xenograft (PDX) model market include JSR Corporation, Wuxi Apptec, The Jackson Laboratory, Charles River Laboratories International, Inc., Taconic Biosciences, Inc., Oncodesign Precision Medicine, Inotiv, Inc., Pharmatest Services, Hera BioLabs, EPO Berlin-Buch GmbH, Xentech, Urosphere, Altogen Labs, and Abnova Corporation. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

  • In January 2023 - Crown Bioscience, a global contract research organization (CRO), acquired the IndivuServ business unit of Indivumed GmbH, a prominent provider of clinical biospecimens. The strategic acquisition created two distinct entities: 'Indivumed Therapeutics' and 'Indivumed Services.' 'Indivumed Services' became a wholly owned subsidiary of Crown Bioscience, incorporating its laboratory operations and staff in Germany and the USA. The acquisition included a biobank with nearly one million samples and a network of over 60 clinical divisions in the United States, Europe, and Asia. This extensive collection and network enhanced Crown Bioscience's biomarker development services and patient-derived xenograft (PDX) platforms. 'Indivumed Therapeutics' continued its focus on individualized cancer therapies through global clinical cooperation. The partnership strengthened precision oncology research and services.

Scope of the Report

Attributes

Details

Years Considered

Historical Data – 2019–2022

Base Year – 2022

Estimated Year – 2023

Forecast Period – 2023–2029

Facts Covered

Revenue in USD Million

Market Coverage

North America, Europe, Asia Pacific, Latin America, Middle East and Africa 

Product/ Service Segmentation

Type, Tumor Type, End User, Region

Key Players

JSR Corporation, Wuxi Apptec, The Jackson Laboratory, Charles River Laboratories International, Inc., Taconic Biosciences, Inc., Oncodesign Precision Medicine, Inotiv, Inc., Pharmatest Services, Hera BioLabs, EPO Berlin-Buch GmbH, Xentech, Urosphere, Altogen Labs, Abnova Corporation

 

By Type

  • Mice Model

  • Rats Model

By Tumor Type

  • Gastrointestinal Tumor Model

  • Gynecological Tumor Model

  • Respiratory Tumor Model

  • Urological Tumor Models

  • Hematological Tumor Models

By End User

  • Pharmaceutical & Biotechnology Companies

  • Academic & Research Institutions

By Region

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East and Africa

  1. Research Framework
    1. Research Objective
    2. Product Overview
    3. Market Segmentation
  2. Executive Summary
  3.  Global Patient-Derived Xenograft (PDX) Model Market Insights
    1. Industry Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
        1. Rising demand for personalized medicine
        2. Growing cancer incidence
      2. Restraints
        1. High cost and technical expertise
        2. Ethical concerns
      3. Opportunities
        1. Expansion in research and development
        2. Collaborations and partnerships
      4. Challenges
        1. Model variability
        2. Regulatory hurdles
    3. Technological Advancements/Recent Developments
    4. Regulatory Framework
    5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  4.  Global Patient-Derived Xenograft (PDX) Model Market Overview
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share and Forecast
      1. By Type
        1. Mice Model
        2. Rats Model
      2. By Tumor Type
        1. Gastrointestinal Tumor Model
        2. Gynecological Tumor Model
        3. Respiratory Tumor Model
        4. Urological Tumor Models
        5. Hematological Tumor Models
        6. Others
      3. By End User
        1. Pharmaceutical & Biotechnology Companies
        2. Academic & Research Institutions
        3. Others
      4. By Region
        1. North America
        2. Europe
        3. Asia Pacific (APAC)
        4. Latin America (LATAM)
        5. Middle East and Africa (MEA)
  5. North America Patient-Derived Xenograft (PDX) Model Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Type
      2. By Tumor Type
      3. By End User
      4. By Country
        1. United States
          1. By Type
          2. By Tumor Type
          3. By End User
        2. Canada
          1. By Type
          2. By Tumor Type
          3. By End User
  6. Europe Patient-Derived Xenograft (PDX) Model Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Type
      2. By Tumor Type
      3. By End User
      4. By Country
        1. Germany
          1. By Type
          2. By Tumor Type
          3. By End User
        2. United Kingdom
          1. By Type
          2. By Tumor Type
          3. By End User
        3. Italy
          1. By Type
          2. By Tumor Type
          3. By End User
        4. France
          1. By Type
          2. By Tumor Type
          3. By End User
        5. Spain
          1. By Type
          2. By Tumor Type
          3. By End User
        6. Belgium
          1. By Type
          2. By Tumor Type
          3. By End User
        7. Russia
          1. By Type
          2. By Tumor Type
          3. By End User
        8. The Netherlands
          1. By Type
          2. By Tumor Type
          3. By End User
        9. Rest of Europe
          1. By Type
          2. By Tumor Type
          3. By End User
  7. Asia-Pacific Patient-Derived Xenograft (PDX) Model Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Type
      2. By Tumor Type
      3. By End User
      4. By Country
        1. China
          1. By Type
          2. By Tumor Type
          3. By End User
        2. India
          1. By Type
          2. By Tumor Type
          3. By End User
        3. Japan
          1. By Type
          2. By Tumor Type
          3. By End User
        4. South Korea
          1. By Type
          2. By Tumor Type
          3. By End User
        5. Australia & New Zealand
          1. By Type
          2. By Tumor Type
          3. By End User
        6. Indonesia
          1. By Type
          2. By Tumor Type
          3. By End User
        7. Malaysia
          1. By Type
          2. By Tumor Type
          3. By End User
        8. Singapore
          1. By Type
          2. By Tumor Type
          3. By End User
        9. Vietnam
          1. By Type
          2. By Tumor Type
          3. By End User
        10. Rest of APAC
          1. By Type
          2. By Tumor Type
          3. By End User
  8. Latin America Patient-Derived Xenograft (PDX) Model Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Type
      2. By Tumor Type
      3. By End User
      4. By Country
        1. Brazil
          1. By Type
          2. By Tumor Type
          3. By End User
        2. Mexico
          1. By Type
          2. By Tumor Type
          3. By End User
        3. Argentina
          1. By Type
          2. By Tumor Type
          3. By End User
        4. Peru
          1. By Type
          2. By Tumor Type
          3. By End User
        5. Rest of LATAM
          1. By Type
          2. By Tumor Type
          3. By End User
  9. Middle East & Africa Patient-Derived Xenograft (PDX) Model Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Type
      2. By Tumor Type
      3. By End User
      4. By Country
        1. Saudi Arabia
          1. By Type
          2. By Tumor Type
          3. By End User
        2. UAE
          1. By Type
          2. By Tumor Type
          3. By End User
        3. Qatar
          1. By Type
          2. By Tumor Type
          3. By End User
        4. Kuwait
          1. By Type
          2. By Tumor Type
          3. By End User
        5. South Africa
          1. By Type
          2. By Tumor Type
          3. By End User
        6. Nigeria
          1. By Type
          2. By Tumor Type
          3. By End User
        7. Algeria
          1. By Type
          2. By Tumor Type
          3. By End User
        8. Rest of MEA
          1. By Type
          2. By Tumor Type
          3. By End User
  10. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Global Patient-Derived Xenograft (PDX) Model Market Share Analysis, 2022
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
  11. Impact of Covid-19 on Global Patient-Derived Xenograft (PDX) Model Market
  12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
    1. JSR Corporation
    2. Wuxi Apptec
    3. The Jackson Laboratory
    4. Charles River Laboratories International, Inc.
    5. Taconic Biosciences, Inc.
    6. Oncodesign Precision Medicine
    7. Inotiv, Inc.
    8. Pharmatest Services
    9. Hera BioLabs
    10. EPO Berlin-Buch GmbH
    11. Xentech
    12. Urosphere
    13. Altogen Labs
    14. Abnova Corporation
    15. Other Prominent Players
  13. Key Strategic Recommendations
  14. Research Methodology
    1.    Qualitative Research
      1.  Primary & Secondary Research
    2.    Quantitative Research
    3.    Market Breakdown & Data Triangulation
      1.  Secondary Research
      2.  Primary Research
    4.    Breakdown of Primary Research Respondents, By Region
    5.    Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

 

List of Figures

Figure 1       Global Patient-Derived Xenograft (PDX) Model Segmentation

Figure 2       Global Patient-Derived Xenograft (PDX) Model Market Value Chain Analysis

Figure 3       Company Market Share Analysis, 2022

Figure 4       Global Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 5       Global Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 6       Global Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 7       Global Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 8       Global Patient-Derived Xenograft (PDX) Model Market Share, By Region, By Value, 2019–2029

Figure 9       North America Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 10     North America Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 11     North America Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 12     North America Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 13     North America Patient-Derived Xenograft (PDX) Model Market Share, By Country, By Value, 2019–2029

Figure 14     United States Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 15     United States Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 16     United States Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 17     United States Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 18     Canada Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 19     Canada Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 20     Canada Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 21     Canada Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 22     Europe Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 23     Europe Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 24     Europe Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 25     Europe Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 26     Europe Patient-Derived Xenograft (PDX) Model Market Share, By Country, By Value, 2019–2029

Figure 27     Germany Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 28     Germany Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 29     Germany Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 30     Germany Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 31     United Kingdom Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 32     United Kingdom Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 33     United Kingdom Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 34     United Kingdom Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 35     Italy Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 36     Italy Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 37     Italy Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 38     Italy Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 39     France Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 40     France Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 41     France Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 42     France Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 43     Spain Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 44     Spain Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 45     Spain Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 46     Spain Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 47     Belgium Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 48     Belgium Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 49     Belgium Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 50     Belgium Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 51     Russia Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 52     Russia Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 53     Russia Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 54     Russia Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 55     The Netherlands Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 56     The Netherlands Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 57     The Netherlands Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 58     The Netherlands Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 59     Rest of Europe Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 60     Rest of Europe Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 61     Rest of Europe Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 62     Rest of Europe Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 63     Asia-Pacific Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 64     Asia-Pacific Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 65     Asia-Pacific Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 66     Asia-Pacific Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 67     Asia-Pacific Patient-Derived Xenograft (PDX) Model Market Share, By Country, By Value, 2019–2029

Figure 68     China Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 69     China Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 70     China Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 71     China Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 72     India Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 73     India Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 74     India Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 75     India Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 76     Japan Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 77     Japan Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 78     Japan Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 79     Japan Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 80     South Korea Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 81     South Korea Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 82     South Korea Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 83     South Korea Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 84     Australia & New Zealand Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 85     Australia & New Zealand Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 86     Australia & New Zealand Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 87     Australia & New Zealand Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 88     Indonesia Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 89     Indonesia Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 90     Indonesia Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 91     Indonesia Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 92     Malaysia Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 93     Malaysia Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 94     Malaysia Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 95     Malaysia Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 96     Singapore Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 97     Singapore Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 98     Singapore Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 99     Singapore Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 100   Vietnam Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 101   Vietnam Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 102   Vietnam Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 103   Vietnam Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 104   Rest of APAC Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 105   Rest of APAC Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 106   Rest of APAC Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 107   Rest of APAC Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 108   Latin America Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 109   Latin America Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 110   Latin America Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 111   Latin America Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 112   Latin America Patient-Derived Xenograft (PDX) Model Market Share, By Country, By Value, 2019–2029

Figure 113   Brazil Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 114   Brazil Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 115   Brazil Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 116   Brazil Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 117   Mexico Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 118   Mexico Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 119   Mexico Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 120   Mexico Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 121   Argentina Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 122   Argentina Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 123   Argentina Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 124   Argentina Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 125   Peru Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 126   Peru Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 127   Peru Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 128   Peru Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 129   Rest of LATAM Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 130   Rest of LATAM Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 131   Rest of LATAM Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 132   Rest of LATAM Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 133   Middle East & Africa Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 134   Middle East & Africa Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 135   Middle East & Africa Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 136   Middle East & Africa Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 137   Middle East & Africa Patient-Derived Xenograft (PDX) Model Market Share, By Country, By Value, 2019–2029

Figure 138   Saudi Arabia Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 139   Saudi Arabia Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 140   Saudi Arabia Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 141   Saudi Arabia Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 142   UAE Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 143   UAE Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 144   UAE Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 145   UAE Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 146   Qatar Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 147   Qatar Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 148   Qatar Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 149   Qatar Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 150   Kuwait Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 151   Kuwait Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 152   Kuwait Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 153   Kuwait Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 154   South Africa Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 155   South Africa Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 156   South Africa Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 157   South Africa Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 158   Nigeria Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 159   Nigeria Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 160   Nigeria Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 161   Nigeria Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 162   Algeria Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 163   Algeria Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 164   Algeria Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 165   Algeria Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Figure 166   Rest of MEA Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Figure 167   Rest of MEA Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Figure 168   Rest of MEA Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Figure 169   Rest of MEA Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

List of Tables

Table 1        Global Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 2 Global Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 3 Global Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 4 Global Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 5 Global Patient-Derived Xenograft (PDX) Model Market Share, By Region, By Value, 2019–2029

Table 6 North America Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 7 North America Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 8 North America Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 9 North America Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 10      North America Patient-Derived Xenograft (PDX) Model Market Share, By Country, By Value, 2019–2029

Table 11      United States Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 12      United States Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 13      United States Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 14      United States Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 15      Canada Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 16      Canada Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 17      Canada Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 18      Canada Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 19      Europe Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 20      Europe Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 21      Europe Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 22      Europe Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 23      Europe Patient-Derived Xenograft (PDX) Model Market Share, By Country, By Value, 2019–2029

Table 24      Germany Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 25      Germany Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 26      Germany Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 27      Germany Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 28      United Kingdom Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 29      United Kingdom Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 30      United Kingdom Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 31      United Kingdom Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 32      Italy Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 33      Italy Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 34      Italy Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 35      Italy Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 36      France Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 37      France Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 38      France Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 39      France Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 40      Spain Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 41      Spain Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 42      Spain Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 43      Spain Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 44      Belgium Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 45      Belgium Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 46      Belgium Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 47      Belgium Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 48      Russia Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 49      Russia Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 50      Russia Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 51      Russia Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 52      The Netherlands Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 53      The Netherlands Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 54      The Netherlands Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 55      The Netherlands Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 56      Rest of Europe Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 57      Rest of Europe Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 58      Rest of Europe Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 59      Rest of Europe Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 60      Asia-Pacific Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 61      Asia-Pacific Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 62      Asia-Pacific Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 63      Asia-Pacific Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 64      Asia-Pacific Patient-Derived Xenograft (PDX) Model Market Share, By Country, By Value, 2019–2029

Table 65      China Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 66      China Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 67      China Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 68      China Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 69      India Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 70      India Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 71      India Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 72      India Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 73      Japan Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 74      Japan Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 75      Japan Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 76      Japan Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 77      South Korea Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 78      South Korea Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 79      South Korea Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 80      South Korea Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 81      Australia & New Zealand Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 82      Australia & New Zealand Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 83      Australia & New Zealand Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 84      Australia & New Zealand Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 85      Indonesia Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 86      Indonesia Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 87      Indonesia Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 88      Indonesia Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 89      Malaysia Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 90      Malaysia Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 91      Malaysia Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 92      Malaysia Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 93      Singapore Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 94      Singapore Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 95      Singapore Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 96      Singapore Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 97      Vietnam Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 98      Vietnam Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 99      Vietnam Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 100    Vietnam Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 101    Rest of APAC Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 102    Rest of APAC Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 103    Rest of APAC Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 104    Rest of APAC Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 105    Latin America Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 106    Latin America Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 107    Latin America Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 108    Latin America Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 109    Latin America Patient-Derived Xenograft (PDX) Model Market Share, By Country, By Value, 2019–2029

Table 110    Brazil Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 111    Brazil Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 112    Brazil Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 113    Brazil Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 114    Mexico Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 115    Mexico Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 116    Mexico Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 117    Mexico Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 118    Argentina Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 119    Argentina Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 120    Argentina Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 121    Argentina Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 122    Peru Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 123    Peru Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 124    Peru Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 125    Peru Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 126    Rest of LATAM Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 127    Rest of LATAM Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 128    Rest of LATAM Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 129    Rest of LATAM Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 130    Middle East & Africa Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 131    Middle East & Africa Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 132    Middle East & Africa Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 133    Middle East & Africa Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 134    Middle East & Africa Patient-Derived Xenograft (PDX) Model Market Share, By Country, By Value, 2019–2029

Table 135    Saudi Arabia Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 136    Saudi Arabia Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 137    Saudi Arabia Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 138    Saudi Arabia Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 139    UAE Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 140    UAE Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 141    UAE Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 142    UAE Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 143    Qatar Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 144    Qatar Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 145    Qatar Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 146    Qatar Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 147    Kuwait Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 148    Kuwait Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 149    Kuwait Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 150    Kuwait Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 151    South Africa Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 152    South Africa Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 153    South Africa Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 154    South Africa Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 155    Nigeria Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 156    Nigeria Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 157    Nigeria Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 158    Nigeria Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 159    Algeria Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 160    Algeria Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 161    Algeria Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 162    Algeria Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 163    Rest of MEA Patient-Derived Xenograft (PDX) Model Market Size, By Value (USD Million), 2019–2029

Table 164    Rest of MEA Patient-Derived Xenograft (PDX) Model Market Share, By Type, By Value, 2019–2029

Table 165    Rest of MEA Patient-Derived Xenograft (PDX) Model Market Share, By Tumor Type, By Value, 2019–2029

Table 166    Rest of MEA Patient-Derived Xenograft (PDX) Model Market Share, By End User, By Value, 2019–2029

Table 167    JSR Corporation Company Overview

Table 168    JSR Corporation Financial Overview

Table 169    Wuxi Apptec Company Overview

Table 170    Wuxi Apptec Financial Overview

Table 171    The Jackson Laboratory Company Overview

Table 172    The Jackson Laboratory Financial Overview

Table 173    Charles River Laboratories International, Inc. Company Overview

Table 174    Charles River Laboratories International, Inc. Financial Overview

Table 175    Taconic Biosciences, Inc. Company Overview

Table 176    Taconic Biosciences, Inc. Financial Overview

Table 177    Oncodesign Precision Medicine Company Overview

Table 178    Oncodesign Precision Medicine Financial Overview

Table 179    Inotiv, Inc. Company Overview

Table 180    Inotiv, Inc. Financial Overview

Table 181    Pharmatest Services Company Overview

Table 182    Pharmatest Services Financial Overview

Table 183    Hera BioLabs Company Overview

Table 184    Hera BioLabs Financial Overview

Table 185    EPO Berlin-Buch GmbH Company Overview

Table 186    EPO Berlin-Buch GmbH Financial Overview

Table 187    Xentech Company Overview

Table 188    Xentech Financial Overview

Table 189    Urosphere Company Overview

Table 190    Urosphere Financial Overview

Table 191    Altogen Labs Company Overview

Table 192    Altogen Labs Financial Overview

Table 193    Abnova Corporation Company Overview

Table 194    Abnova Corporation Financial Overview

Market Segmentation

No data available
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: Global Patient-Derived Xenograft (PDX) Model Market size was estimated at USD 312.56 million in 2022.
Ans: Global Patient-Derived Xenograft (PDX) Model Market size is expected to grow at a CAGR of 13.1% during the forecast period between 2023 and 2029.
Ans: Global Patient-Derived Xenograft (PDX) Model Market size is expected to reach a value of USD 654.91 million by 2029.
Ans: Major factors driving the growth of the Global Patient-Derived Xenograft (PDX) Model Market include the rising demand for personalized medicine and growing cancer incidence.
Ans: Key players in the Global Patient-Derived Xenograft (PDX) Model Market include JSR Corporation, Wuxi Apptec, The Jackson Laboratory, Charles River Laboratories International, Inc., Taconic Biosciences, Inc., Oncodesign Precision Medicine, Inotiv, Inc., Pharmatest Services, Hera BioLabs, EPO Berlin-Buch GmbH, Xentech, Urosphere, Altogen Labs, and Abnova Corporation.
Ans: The mice model segment holds a higher market share in the Global Patient-Derived Xenograft (PDX) Model Market by type.
Ans: The respiratory tumor model segment accounts for the highest market share in the Global Patient-Derived Xenograft (PDX) Model Market by tumor type.
Ans: North America holds the highest market share in the Global Patient-Derived Xenograft (PDX) Model Market.